Efficacy and safety of nintedanib combined with pirfenidone versus monotherapy in patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis
American Journal of Translational Research · 2026 · 18 (5) · 3864-3885
DOI: 10.62347/pmfb6027 ↗At a glance
Übersichtsarbeit in American Journal of Translational Research, 2026. Written by Shengbo Xu and 3 co-authors. Institution: Guangxi University of Chinese Medicine Nanning 530200, Guangxi, P. R. China. The full text is freely available in PubMed Central.
Abstract (original language)
Ebda abstract disponibbli.
Subjects
Author keywords
Authors and institutions
- Guangxi University of Chinese Medicine Nanning 530200, Guangxi, P. R. China.
- Department of Respiratory and Critical Care Medicine, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine Nanning 530011, Guangxi, P. R. China.
Cite
APA
Xu, S., Li, L., Lu, W., & Liu, R. (2026). Efficacy and safety of nintedanib combined with pirfenidone versus monotherapy in patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis. American Journal of Translational Research, 18(5), 3864-3885. https://doi.org/10.62347/pmfb6027
Vancouver
Xu S, Li L, Lu W, Liu R. Efficacy and safety of nintedanib combined with pirfenidone versus monotherapy in patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis. American Journal of Translational Research. 2026;18(5):3864-3885. doi:10.62347/pmfb6027
BibTeX
@article{Xu2026,
author = {Xu, Shengbo and Li, Lan and Lu, Wen and Liu, Rui},
title = {Efficacy and safety of nintedanib combined with pirfenidone versus monotherapy in patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis},
journal = {American Journal of Translational Research},
year = {2026},
volume = {18},
number = {5},
pages = {3864--3885},
doi = {10.62347/pmfb6027}
}
EUVIMED